Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement

Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement
Committee Meeting on July 19, 2011, from 8 a.m. to 5 p.m.

Agenda: On July 19, 2011, the committee will discuss new drug application (NDA) 202293 dapagliflozin, manufactured by Bristol-Myers Squibb and AstraZeneca. Dapagliflozin is the first drug in the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.